Evidence map›Paper›PMID 21048103›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

Re-examination of CD91 function in GRP94 (glycoprotein 96) surface binding, uptake, and peptide cross-presentation.

Angela R Jockheck-Clark, Edith V Bowers, Mariam B Totonchy, Julie Neubauer, Salvatore V Pizzo, Christopher V Nicchitta

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Angela R Jockheck-ClarkDepartment of Cell Biology, Duke University Medical Center, Durham NC 27710, USA.
Edith V Bowers
Mariam B Totonchy
Julie Neubauer
Salvatore V Pizzo
Christopher V Nicchitta
Duke University · USDuke Medical Center · USDuke University Hospital · USInstitute of Cell Biology · UA

Funding

Duke University Center for Translational ResearchP30AI051445 · NIAID · DUKE UNIVERSITY · PI FROTHINGHAM, RICHARD · 2002 to 2006
$8.1M
Regulation of mRNA Partitioning to the Endoplasmic ReticulumR01GM077382 · NIGMS · DUKE UNIVERSITY · PI NICCHITTA, CHRISTOPHER V. · 2007 to 2010
$1.5M
Mechanism of Chaperone-Mediated Tumor RejectionR01CA104392 · NCI · DUKE UNIVERSITY · PI NICCHITTA, CHRISTOPHER V. · 2004 to 2008
$1.2M
CELL RECEPTORS IN COAGULATION AND ATHEROGENESISR01HL024066 · NHLBI · DUKE UNIVERSITY · PI PIZZO, SALVATORE V · 1985 to 2006
$1.2M
CELL RECEPTORS IN COAGULATION AND ATHEROGENESISR37HL024066 · NHLBI · DUKE UNIVERSITY · PI PIZZO, SALVATORE V · 1993 to 2001
$502k
NCI NIH HHS CA-104392NCI NIH HHS R01 CA104392NHLBI NIH HHS HL-24066NHLBI NIH HHS R01 HL024066NHLBI NIH HHS R37 HL024066NIAID NIH HHS AI-51445NIAID NIH HHS P30 AI051445NIGMS NIH HHS GM-077382NIGMS NIH HHS R01 GM077382
6 · The paper itself

Abstract

GRP94 (gp96)-peptide complexes can be internalized by APCs and their associated peptides cross-presented to yield activation of CD8(+) T cells. Investigations into the identity (or identities) of GRP94 surface receptors have yielded conflicting results, particularly with respect to CD91 (LRP1), which has been proposed to be essential for GRP94 recognition and uptake. To assess CD91 function in GRP94 surface binding and endocytosis, these parameters were examined in mouse embryonic fibroblast (MEF) cell lines whose expression of CD91 was either reduced via RNA interference or eliminated by genetic disruption of the CD91 locus. Reduction or loss of CD91 expression abrogated the binding and uptake of receptor-associated protein, an established CD91 ligand. Surface binding and uptake of an N-terminal domain of GRP94 (GRP94.NTD) was unaffected. GRP94.NTD surface binding was markedly suppressed after treatment of MEF cell lines with heparin, sodium chlorate, or heparinase II, demonstrating that heparin sulfate proteoglycans can function in GRP94.NTD surface binding. The role of CD91 in the cross-presentation of GRP94-associated peptides was examined in the DC2.4 dendritic cell line. In DC2.4 cells, which express CD91, GRP94.NTD-peptide cross-presentation was insensitive to the CD91 ligands receptor-associated protein or activated α(2)-macroglobulin and occurred primarily via a fluid-phase, rather than receptor-mediated, uptake pathway. These data clarify conflicting data on CD91 function in GRP94 surface binding, endocytosis, and peptide cross-presentation and identify a role for heparin sulfate proteoglycans in GRP94 surface binding.

Indexed as

Amino Acid SequenceAnimalsAntigens, CDCell LineCell MembraneCross-PrimingDogsEndocytosisHeat-Shock ProteinsHeparan Sulfate ProteoglycansLigandsLow Density Lipoprotein Receptor-Related Protein-1Membrane GlycoproteinsMiceMice, Inbred C57BLMice, TransgenicAntigens, CDendoplasminHeat-Shock ProteinsHeparan Sulfate ProteoglycansLigandsLow Density Lipoprotein Receptor-Related Protein-1Lrp1 protein, mouseMembrane GlycoproteinsPeptide FragmentsReceptors, LDLTumor Suppressor Proteins

Identifiers

PMID21048103
PMCPMC3717329
OpenAlexW2102643650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.